Eli Lilly and Co. and ImaginAb Inc. have entered preclinical research collaboration to study potential novel T-cell-based immuno-oncology therapies. Financial terms were not disclosed. ImaginAb will conduct preclinical research using its immune imaging agent, IAB22M2C (a clinical anti-human CD8 probe), to detect T-cell trafficking, redirection and infiltration in response to Lilly oncology molecules. ImaginAb maintains full rights to its imaging agents used as part of the research project.  ...